Corvus Pharmaceuticals, Inc.
CRVS
$6.93
-$0.32-4.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.14M | -41.40M | -62.29M | -56.83M | -22.62M |
| Total Depreciation and Amortization | 92.00K | 84.00K | 85.00K | 93.00K | 102.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.49M | 14.50M | 38.43M | 35.19M | 2.62M |
| Change in Net Operating Assets | 1.72M | -1.71M | -1.65M | -579.00K | -1.35M |
| Cash from Operations | -28.83M | -28.53M | -25.42M | -22.13M | -21.24M |
| Capital Expenditure | -149.00K | -36.00K | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | 5.00K | 5.00K | 5.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.89M | -23.20M | -27.49M | -23.72M | -2.28M |
| Cash from Investing | -26.03M | -23.23M | -27.48M | -23.72M | -2.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 54.71M | 35.34M | 35.06M | 16.46M | 16.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 13.97M | 13.97M | 13.97M | 13.97M |
| Cash from Financing | 54.71M | 49.31M | 49.03M | 30.42M | 30.71M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.00K | -2.46M | -3.88M | -15.43M | 7.18M |